Suchergebnisse - "Rider, Alex"

PubPharm (45)

1

Real-world clinical profile, RET mutation testing, treatments, and PROs for MTC in Europe

enthalten in: European thyroid journal | 2024

von Segall, G. | Singh, R. | Jen, M. | +4

2

Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan

enthalten in: Future oncology (London, England) | 2023

von Fukuda, N. | Tanizawa, Y. | Nakamura, K. | +7

3

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel

enthalten in: Advances in therapy | 2023

von Mahtani, R. | Niyazov, A. | Lewis, K. | +4

4

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer : Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel

enthalten in: Breast (Edinburgh, Scotland) | 2022

von Mahtani, R. | Niyazov, A. | Arondekar, B. | +4

5

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel

enthalten in: BMC cancer | 2022

von Mahtani, R. | Niyazov, A. | Arondekar, B. | +4

6

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

enthalten in: BMC cancer | 2022

von Mahtani, R. | Niyazov, A. | Arondekar, B. | +4

7

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

enthalten in: BMC cancer | 2022

von Mahtani, R. | Niyazov, A. | Arondekar, B. | +4

8

BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer : Real-World Data from the United States, Europe, and Israel

enthalten in: Cancers | 2022

von Mahtani, R. | Niyazov, A. | Arondekar, B. | +4

9

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in the United States, Europe, and Israel

enthalten in: Advances in therapy | 2022

von Mahtani, R. | Niyazov, A. | Lewis, K. | +4

10

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in the United States, Europe, and Israel

enthalten in: Advances in therapy | 2022

von Mahtani, R. | Niyazov, A. | Lewis, K. | +4

1
2
3
4
5
Nächster »
[5]